Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer

Future Oncol. 2021 Mar;17(8):931-941. doi: 10.2217/fon-2020-1021. Epub 2020 Nov 19.

Abstract

Aim: This study examined treatment patterns and effectiveness outcomes of patients with metastatic triple-negative breast cancer (mTNBC) from US community oncology centers. Materials & methods: Eligible patients were females, aged ≥18 years, diagnosed with mTNBC between 1 January 2010 and 31 January 2016. Kaplan-Meier and Cox regression methods were used. Results: Sample comprised 608 patients with average age of 57.5 years and 505/608 patients (83.1%) received systemic treatment. Overall survival (OS) from first-line treatment found that African-American patients had shorter OS than White (9.3 vs 13.7 months; hazard ratio: 1.35; p = 0.006). Conclusion: More than 15% of women with mTNBC were not treated, indicating a high unmet need. Overall prognosis remains poor, which highlights the opportunity for newer therapies to improve progression-free survival and OS.

Keywords: African–American patients; community oncology; metastatic triple-negative breast cancer; overall survival; progression-free survival; treatment patterns.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Black or African American / statistics & numerical data
  • Disease Progression
  • Female
  • Health Services Needs and Demand / statistics & numerical data*
  • Health Status Disparities
  • Humans
  • Kaplan-Meier Estimate
  • Middle Aged
  • Neoplasm Staging
  • Practice Patterns, Physicians' / organization & administration
  • Practice Patterns, Physicians' / statistics & numerical data*
  • Prognosis
  • Progression-Free Survival
  • Retrospective Studies
  • Triple Negative Breast Neoplasms / diagnosis
  • Triple Negative Breast Neoplasms / drug therapy*
  • Triple Negative Breast Neoplasms / mortality
  • Triple Negative Breast Neoplasms / secondary
  • White People / statistics & numerical data

Grants and funding